{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009044","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.520438+00:00","generated_at":"2026-06-17T21:31:50.825049+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology FY2022 net loss $120.7M; CFO promoted to CFO & COO","bullets":["Net loss $120.7M ($3.65/share) vs $76.0M ($8.95) in 2021; R&D spend rose to $86.1M from $51.0M.","Cash $180.7M with no debt as of Dec 31, 2022; runway into 1H 2025.","Two Phase 1 trials for PYX-201 and PYX-106 initiated; preliminary data expected late 2023 to early 2024.","CFO Pam Connealy promoted to additional role of COO effective March 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009044","json":"https://secwatch.observer/filing/0000950170-23-009044.json","markdown":"https://secwatch.observer/filing/0000950170-23-009044.md","text":"https://secwatch.observer/filing/0000950170-23-009044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/pyxs-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:31:50.825049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be09e8c3b228a0b3a30de91f61a04782bd96a186","claim":"Pyxis Oncology, Inc. reported the full year ended December 31, 2022 results: net income $120.7 million, EPS ($3.65) per common share.","evidence_excerpt":"Net loss was $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022, compared to $76.0 million, or ($8.95) per common share, for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"$120.7 million"},{"label":"EPS","value":"($3.65) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e670186208","claim":"Pamela Connealy changed role as Chief Financial Officer and Chief Operating Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017023009044/0000950170-23-009044-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Financial Officer and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}